NO924780L - Ekspresjon av spesifikke immunogener ved bruk av virusantigener - Google Patents
Ekspresjon av spesifikke immunogener ved bruk av virusantigenerInfo
- Publication number
- NO924780L NO924780L NO92924780A NO924780A NO924780L NO 924780 L NO924780 L NO 924780L NO 92924780 A NO92924780 A NO 92924780A NO 924780 A NO924780 A NO 924780A NO 924780 L NO924780 L NO 924780L
- Authority
- NO
- Norway
- Prior art keywords
- nucleotide sequence
- peptides
- antigens
- expression
- encoding
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 241000700605 Viruses Species 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000712431 Influenza A virus Species 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 102400000368 Surface protein Human genes 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80510591A | 1991-12-11 | 1991-12-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO924780D0 NO924780D0 (no) | 1992-12-10 |
| NO924780L true NO924780L (no) | 1993-06-14 |
Family
ID=25190685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO92924780A NO924780L (no) | 1991-12-11 | 1992-12-10 | Ekspresjon av spesifikke immunogener ved bruk av virusantigener |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5591823A (fr) |
| EP (1) | EP0546787A3 (fr) |
| JP (1) | JPH05262667A (fr) |
| KR (1) | KR930013112A (fr) |
| CN (1) | CN1073878A (fr) |
| AU (1) | AU2981992A (fr) |
| BR (1) | BR9204978A (fr) |
| CA (1) | CA2084180A1 (fr) |
| CZ (1) | CZ362692A3 (fr) |
| FI (1) | FI925590A (fr) |
| HU (2) | HUT65366A (fr) |
| IL (1) | IL103928A0 (fr) |
| MX (1) | MX9207113A (fr) |
| NO (1) | NO924780L (fr) |
| SK (1) | SK362692A3 (fr) |
| TW (1) | TW239162B (fr) |
| ZA (1) | ZA929355B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0633929B1 (fr) * | 1992-04-01 | 2004-03-03 | The Rockefeller University | PROCEDE PERMETTANT DE FAIRE PROLIFERER $i(IN VITRO) DES PRECURSEURS DE CELLULES DENDRITIQUES ET UTILISATION DE CELLES-CI POUR PRODUIRE DES IMMUNOGENES |
| EP0671926B1 (fr) * | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Peptides immunomodulateurs |
| WO1995007099A1 (fr) * | 1993-09-09 | 1995-03-16 | The Nisshin Oil Mills, Ltd. | Vaccin et procede pour sa production |
| EP2374894B1 (fr) * | 1993-09-13 | 2014-09-17 | Protein Sciences Corporation | Procédé pour la production de vaccins polyvalents contre l'hémagglutinine de la grippe |
| US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| DE69535716T2 (de) * | 1995-05-26 | 2009-03-19 | Protein Sciences Corp., Meriden | Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| AU7471098A (en) * | 1997-04-30 | 1998-11-24 | Mount Sinai School Of Medicine Of The City University Of New York, The | Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents |
| US6274378B1 (en) | 1997-10-27 | 2001-08-14 | The Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
| AU2872199A (en) | 1998-02-20 | 1999-09-06 | Rockefeller University, The | Apoptotic cell-mediated antigen presentation to dendritic cells |
| AU2002223398A1 (en) * | 2000-08-10 | 2002-04-08 | Tsinghua University | A vaccine for influenza virus and its preparation |
| JP2004508977A (ja) | 2000-09-11 | 2004-03-25 | ダウ グローバル テクノロジーズ インコーポレイティド | ランフラットタイヤ支持体 |
| WO2004091491A2 (fr) * | 2003-04-10 | 2004-10-28 | Transform Pharmaceuticals, Inc. | Profilage de variants conformationnels, compositions anticorps et procedes d'utilisation associes |
| CA2610667A1 (fr) * | 2005-06-01 | 2006-12-07 | Variation Biotechnologies Inc. | Formulation peptidique de vaccin antigrippal |
| WO2007084568A2 (fr) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Bio-essai de suivi en hétéroduplex |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2012122A1 (fr) * | 2007-07-06 | 2009-01-07 | Medigene AG | Protéines structurelles de parvovirus muté |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| AU2008293504B2 (en) * | 2007-08-27 | 2012-04-12 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| KR101705150B1 (ko) | 2008-10-22 | 2017-02-22 | 온코세라피 사이언스 가부시키가이샤 | Ｒａｂ６ｋｉｆｌ／ｋｉｆ２０ａ 에피토프 펩티드 및 이를 포함하는 백신 |
| CN101708442B (zh) * | 2009-09-04 | 2011-08-24 | 山东中惠仪器有限公司 | 全自动标准气体配制装置 |
| CA2793959C (fr) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Glycoproteines du cmv et vecteurs recombines |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (fr) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Particules virales dérivées d'un virus enveloppé |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3069730A3 (fr) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
| EP3072901A1 (fr) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Trimères de glycoprotéines de l'enveloppe du vih-1 soluble |
| US10063211B2 (en) * | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| RU2022108149A (ru) * | 2016-02-03 | 2022-05-05 | СиДжи ДИСКАВЕРИ, ИНК. | Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339504A3 (fr) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères |
| US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| EP0492920A1 (fr) * | 1990-12-24 | 1992-07-01 | Merck & Co. Inc. | Vaccine chimérique de l'influenza et de l'HIV |
-
1992
- 1992-11-30 IL IL103928A patent/IL103928A0/xx unknown
- 1992-11-30 CA CA002084180A patent/CA2084180A1/fr not_active Abandoned
- 1992-12-01 JP JP4321768A patent/JPH05262667A/ja active Pending
- 1992-12-02 AU AU29819/92A patent/AU2981992A/en not_active Abandoned
- 1992-12-02 ZA ZA929355A patent/ZA929355B/xx unknown
- 1992-12-07 TW TW081109778A patent/TW239162B/zh active
- 1992-12-07 EP EP19920311146 patent/EP0546787A3/en not_active Withdrawn
- 1992-12-09 FI FI925590A patent/FI925590A/fi not_active Application Discontinuation
- 1992-12-09 KR KR1019920023656A patent/KR930013112A/ko not_active Application Discontinuation
- 1992-12-09 MX MX9207113A patent/MX9207113A/es unknown
- 1992-12-10 CN CN92113703A patent/CN1073878A/zh active Pending
- 1992-12-10 NO NO92924780A patent/NO924780L/no unknown
- 1992-12-10 CZ CS923626A patent/CZ362692A3/cs unknown
- 1992-12-10 BR BR9204978A patent/BR9204978A/pt not_active Application Discontinuation
- 1992-12-10 SK SK3626-92A patent/SK362692A3/sk unknown
- 1992-12-11 HU HU9203931A patent/HUT65366A/hu unknown
-
1993
- 1993-12-17 US US08/169,813 patent/US5591823A/en not_active Expired - Lifetime
-
1995
- 1995-06-27 HU HU95P/P00456P patent/HU211548A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO924780D0 (no) | 1992-12-10 |
| TW239162B (fr) | 1995-01-21 |
| AU2981992A (en) | 1993-06-17 |
| US5591823A (en) | 1997-01-07 |
| FI925590A (fi) | 1993-06-12 |
| HU9203931D0 (en) | 1993-04-28 |
| FI925590A0 (fi) | 1992-12-09 |
| CZ362692A3 (en) | 1994-02-16 |
| EP0546787A2 (fr) | 1993-06-16 |
| EP0546787A3 (en) | 1994-06-01 |
| HUT65366A (en) | 1994-05-02 |
| ZA929355B (en) | 1994-06-02 |
| MX9207113A (es) | 1994-05-31 |
| BR9204978A (pt) | 1993-06-15 |
| SK362692A3 (en) | 1995-11-08 |
| KR930013112A (ko) | 1993-07-21 |
| JPH05262667A (ja) | 1993-10-12 |
| HU211548A9 (en) | 1995-12-28 |
| IL103928A0 (en) | 1993-04-04 |
| CA2084180A1 (fr) | 1993-06-12 |
| CN1073878A (zh) | 1993-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO924780L (no) | Ekspresjon av spesifikke immunogener ved bruk av virusantigener | |
| ATE295895T1 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| BR0207067A (pt) | Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo | |
| SE8701413D0 (sv) | Expression and purification of an htlv-iii gag/env gene protein | |
| DE69533912D1 (de) | Antikörper gegen Epitope mit Homologie zu Auto-Antigenen, Verfahren zur Herstellung und deren Verwendungen | |
| BR9406595A (pt) | Processo para a preparação dos imunógenos ou reagentes para diagnóstico que mimetizam um antigeno ou um organismo patogênico especifico para uma doença fagos vacinas contra um agente patogênico especifico e plasmideos pc89 modificados | |
| Lawson et al. | Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: a model for the study of molecular mimicry in the pathogenesis of viral myocarditis. | |
| NO963508L (no) | Urease-basert vaksine og behandling av Helicobacter-infeksjon | |
| RU95122726A (ru) | Способ получения иммуногенов или диагностических реагентов, а также иммуногены и диагностические реагенты, получаемые с его помощью | |
| SE8604007L (sv) | Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids) | |
| NO962426L (no) | Spermieantigen som tilsvarer et spermie zonabindende protein autoantigenepitop | |
| HUP9903770A2 (hu) | Eljárások és készítmények többepitópos antigének konformációjának megváltoztatására immunválasz kiváltása céljából | |
| WO1996021734A3 (fr) | Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques | |
| NO20053363L (no) | Malrettede enkle epitoper. | |
| NO954318D0 (no) | Immunogent preparat av OspC-antigenvaksiner for forhindring og behandling av Lymesykdom, samt rekombinante fremgangsmåter for fremstilling av slike antigener | |
| ATE382696T1 (de) | Immunoreaktive antigene des hepatitis e viruses | |
| MX9801089A (es) | Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna. | |
| DE68923286D1 (de) | Impfstoffe und testsätze für haemophilus influenzae. | |
| ATE189683T1 (de) | Hcv peptidantigene und verfahren zur bestimmung von hcv | |
| WO1996012190A3 (fr) | Presentation d'antigenes hydrophobes a des lymphocytes t par des molecules cd1 | |
| Morita et al. | Antigenic memory in man in response to sequential infections with influenza A viruses | |
| Parry et al. | A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles. | |
| Hudecz et al. | Preparation of highly purified human cytomegalovirus envelope antigen | |
| EP0370090B1 (fr) | Immunogenes et peptides biologiquement actifs derives de sequences partagees d'antigenes et d'anticorps anti-idiotypiques ou d'anticorps specifiques contre des recepteurs cellulaires des antigenes | |
| BR9905780A (pt) | Antìgenos vacinais de leptospira para prevenção da laptospirose |